Anti-Phosphatidylcholines Antibodies in Acute Myocardial Infarction: a case-controlled study

Background:Acute myocardial infarction (AMI) is the combined result of environmental factors andpersonal predispositions. Many factors play a role in AMI. One those anti-Phospholipid (aPL)antibodies, that may act in the induction of immunological response leading to thedevelopment of AMI. Anti-Phosphatidylcholines (PC) antibody is detected in variousdiseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipidantibody syndrome. The study of anti-PC antibody in AMI might shed light on etiologicmechanisms in the pathogenesis of acute coronary syndromes. This study was designed toinvestigate whether prevalence of anti-PC antibodies, in patients who had AMI and toanalyze their relationship with traditional cardiovascular risk factors.Materials and Methods:The prevalence of anti-PC IgG and IgM in a well characterized group of patients with AMI asa case group and in age and sex matched healthy subjects as control group. Sera from the caseand the control groups were tested to evaluate the presence of IgG and IgM isotypes to anti-PC by ELISA method.Results:The prevalence of anti-PC IgG and also IgM in the case group resulted significantly higherthan in the control group with AMI (p<0.005).Conclusion:Our findings suggest that anti-PC antibodies seemed to play a role in AMI, independent riskfactors for AMI, which may represent a link between autoimmunity and atherosclerosis inpatients with AMI. Further studies with bigger sample size including patients with AMI andhealthy people are needed to explore the exact role of anti-PC antibodies in AMI.